Indications And Dose
Treatment of venous thromboembolism in pregnancy ▶BY SUBCUTANEOUS INJECTION ▶Adult (body-weight up to 50 kg): 40 mg twice daily, dose based on early pregnancy body-weight ▶Adult (body-weight 50–69 kg): 60 mg twice daily, dose based on early pregnancy body-weight ▶Adult (body-weight 70–89 kg): 80 mg twice daily, dose based on early pregnancy body-weight ▶Adult (body-weight 90 kg and above): 100 mg twice daily, dose based on early pregnancy body-weight Prophylaxis of deep-vein thrombosis, especially in surgical patients—moderate risk ▶BY SUBCUTANEOUS INJECTION ▶Adult: 20 mg for 1 dose, dose to be given approximately 2 hours before surgery, then 20 mg every 24 hours Prophylaxis of deep-vein thrombosis, especially surgical patients—high risk (e.g. orthopaedic surgery) ▶BY SUBCUTANEOUS INJECTION ▶Adult: 40 mg for 1 dose, dose to be given 12 hours before surgery, then 40 mg every 24 hours Prophylaxis of deep-vein thrombosis in medical patients ▶BY SUBCUTANEOUS INJECTION ▶Adult: 40 mg every 24 hours Treatment of deep-vein thrombosis in uncomplicated patients with low risk of recurrence | Treatment of pulmonary embolism in uncomplicated patients with low risk of recurrence ▶BY SUBCUTANEOUS INJECTION ▶Adult: 1.5 mg/kg every 24 hours until adequate oral anticoagulation established Treatment of deep-vein thrombosis in patients with risk factors such as obesity, cancer, recurrent VTE, or proximal thrombosis | Treatment of pulmonary embolism in patients with risk factors such as obesity, symptomatic pulmonary embolism, cancer, or recurrent VTE ▶BY SUBCUTANEOUS INJECTION ▶Adult: 1 mg/kg every 12 hours until adequate oral anticoagulation established Treatment of acute ST-segment elevation myocardial infarction (patients not undergoing percutaneous coronary intervention) ▶INITIALLY BY INTRAVENOUS INJECTION ▶Adult 18–74 years: Initially 30 mg, followed by (by subcutaneous injection) 1 mg/kg for 1 dose, then (by subcutaneous injection) 1 mg/kg every 12 hours (max. per dose 100 mg) for up to 8 days, maximum dose applies for the first two subcutaneous doses only ▶BY SUBCUTANEOUS INJECTION ▶Adult 75 years and over: 750 micrograms/kg every 12 hours (max. per dose 75 mg), maximum dose applies for the first two doses only Treatment of acute ST-segment elevation myocardial infarction (patients undergoing percutaneous coronary intervention) ▶INITIALLY BY INTRAVENOUS INJECTION ▶Adult 18–74 years: Initially 30 mg, followed by (by subcutaneous injection) 1 mg/kg for 1 dose, then (by subcutaneous injection) 1 mg/kg every 12 hours (max. per dose 100 mg) for up to 8 days, maximum dose applies for the first two subcutaneous doses only, then (by intravenous injection) 300 micrograms/kg for 1 dose, dose to be given at the time of procedure if the last subcutaneous dose was given more than 8 hours previously ▶INITIALLY BY SUBCUTANEOUS INJECTION ▶Adult 75 years and over: 750 micrograms/kg every 12 hours (max. per dose 75 mg), maximum dose applies for the first two doses only, then (by intravenous injection) 300 micrograms/kg for 1 dose, dose to be given at the time of procedure if the last subcutaneous dose was given more than 8 hours previously Unstable angina | Non-ST-segment-elevation myocardial infarction ▶BY SUBCUTANEOUS INJECTION ▶Adult: 1 mg/kg every 12 hours usually for 2–8 days (minimum 2 days) Prevention of clotting in extracorporeal circuits ▶TO THE DEVICE AS A FLUSH ▶Adult: (consult product literature) DOSE EQUIVALENCE AND CONVERSION ▶1 mg equivalent to 100 units. l UNLICENSED USE Not licensed for treatment of venous thromboembolism in pregnancy.
PDF page 164